"The Johns Hopkins Center for Immunization Research facilitates the development of new vaccines and expands research activities in vaccine development, evaluation and policy. The Center is currently conducting clinical trials for COVID-19 investigational vaccines. Since its founding by Dr. Mary Lou Clements-Mann in 1985, the CIR has been dedicated to the advancement of vaccine research for infectious diseases. Some of our partners include the US National Institutes of Health (NIH), Department of Defense (DOD) as well as private sector sponsors to conduct phase I, II and III clinical trials for infectious agents like COVID-19, RSV, Dengue, ETEC, Ebola, Zika, Malaria, HMPV, West Nile, Avian Flu, HIV and HPV."

During the past decade, Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health conducted 24 clinical trials. In the 10-year time frame, 24 clinical trials started and 12 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 6 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health" #1 sponsor was "National Institute of Allergy and Infectious Diseases (NIAID)" with 47 trials, followed by "Johns Hopkins Bloomberg School of Public Health" with 9 trials sponsored, "PATH" with 4 trials sponsored, "TD Vaccines A/S" with 1 trials sponsored and "U.S. Army Medical Research and Development Command" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health" #1 collaborator was "Johns Hopkins Bloomberg School of Public Health" with 13 trials as a collaborator, "Naval Medical Research Center" with 6 trials as a collaborator, "United States Department of Defense" with 3 trials as a collaborator, "ANRS, Emerging Infectious Diseases" with 1 trials as a collaborator and "Centers for Disease Control and Prevention" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health" are "Dengue" (16 trials), "Respiratory Syncytial Virus Infections" (9 trials), "HIV Infections" (6 trials), "Dengue Fever" (4 trials) and "Diarrhea" (4 trials). Many other conditions were trialed in "Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health" in a lesser frequency.

Most popular intervention types in "Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health" are "Biological" (61 trials), "Drug" (3 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (33 trials), "Placebo Vaccine" (3 trials), "rDEN1delta30" (3 trials), "ACE527" (2 trials) and "RSV LID cp ΔM2-2 Vaccine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health" are 61 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 56 completed trials in Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, 1 suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Center for Immunization Research, Johns Hopkins Bloomberg School of Public Health, 54 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".